Isofol Medical AB (ISOFOL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Isofol Medical AB (ISOFOL) has a cash flow conversion efficiency ratio of -0.089x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.78 Million ≈ $-1.16 Million USD) by net assets (Skr120.62 Million ≈ $12.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Isofol Medical AB net asset quality index to measure how much of total assets are equity-financed.
Isofol Medical AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Isofol Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Isofol Medical AB debt service capacity to assess how comfortably operating cash covers total debt obligations.
Isofol Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Isofol Medical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grand Kartech Tbk
JK:KRAH
|
0.061x |
|
Almaden Minerals Ltd
TO:AMM
|
-0.200x |
|
Dayou AP Co.Ltd
KQ:290120
|
-0.077x |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
-0.364x |
|
NeuPath Health Inc
V:NPTH
|
-0.010x |
|
Aligos Therapeutics Inc
NASDAQ:ALGS
|
-0.728x |
|
Australian Gold and Copper Ltd
AU:AGC
|
-0.013x |
|
West High Yield Resources Ltd
V:WHY
|
0.104x |
Annual Cash Flow Conversion Efficiency for Isofol Medical AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Isofol Medical AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see ISOFOL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr107.87 Million ≈ $11.61 Million |
Skr-51.94 Million ≈ $-5.59 Million |
-0.481x | +10.62% |
| 2024-12-31 | Skr77.94 Million ≈ $8.39 Million |
Skr-41.99 Million ≈ $-4.52 Million |
-0.539x | -24.51% |
| 2023-12-31 | Skr121.43 Million ≈ $13.07 Million |
Skr-52.54 Million ≈ $-5.65 Million |
-0.433x | +64.10% |
| 2022-12-31 | Skr158.48 Million ≈ $17.05 Million |
Skr-190.97 Million ≈ $-20.55 Million |
-1.205x | -103.52% |
| 2021-12-31 | Skr318.23 Million ≈ $34.25 Million |
Skr-188.43 Million ≈ $-20.28 Million |
-0.592x | +75.41% |
| 2020-12-31 | Skr66.57 Million ≈ $7.16 Million |
Skr-160.27 Million ≈ $-17.25 Million |
-2.408x | -71.58% |
| 2019-12-31 | Skr104.91 Million ≈ $11.29 Million |
Skr-147.21 Million ≈ $-15.84 Million |
-1.403x | -302.20% |
| 2018-12-31 | Skr265.01 Million ≈ $28.52 Million |
Skr-92.46 Million ≈ $-9.95 Million |
-0.349x | -93.21% |
| 2017-12-31 | Skr343.03 Million ≈ $36.92 Million |
Skr-61.94 Million ≈ $-6.67 Million |
-0.181x | +98.06% |
| 2016-12-31 | Skr6.10 Million ≈ $656.35K |
Skr-56.90 Million ≈ $-6.12 Million |
-9.330x | +66.45% |
| 2015-12-31 | Skr1.32 Million ≈ $142.27K |
Skr-36.77 Million ≈ $-3.96 Million |
-27.812x | -- |
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.